This site is intended for UK Healthcare professionals only

Are you a UK Healthcare professional?

We are unfortunately unable to allow patients to attend CPC

CPC 2022 Programme

Subpage Hero

.

Loading

Beyond Bisphosphonates: The Emerging Role of Anabolic Agents in The Treatment of Osteoporosis

14 May 2022
Strategy and Policy

For many years bisphosphonates and anti-resorptive agents have been the main stay of osteoporosis treatment. Though effective at preventing fractures, they are not able to improve bone density. Anabolic agents including Teriparatide and Romosozumab are enabling us to proactively improve bone density. Will using anabolic agents followed by anti-resorptives be the new way we treat osteoporosis?

 

Learning outcomes:

  • What is osteoporosis
  • How is it traditionally managed
  • Place in therapy of teriparatide and Romosozumab in osteoporosis

 

Speakers
Mrs Joanna Rees, Advanced Pharmacist - Hywel Dda University Health Board

Partners

Lead Education Partner

  • CPPE
  • Morph

 

Education Partner

  • APTUK
  • BOPA
  • BPNG
  • CMHP
  • Health Education England

 

Education Partner

  • HIVPA
  • UKRPG
  • NHS England and NHS Improvement
  • NHS Digital
  • NHSx
  • PTOC
  • GPHC

 

Education Partner

  • NPPG
  • PCPA
  • PDA
  • Pharmacist Support
  • RPUK
  • SPS

 

Education Partner

  • Soar Beyond
  • NHCA
  • UKBPA
  • UKCPA
  • PrescQIPP
  • Pharmacy Declares
  • GHP and RPS

 

Media Partner

  • C&D
  • PDA
  • PrescQIPP
  • Scottish Healthcare Review
  • Welsh Healthcare Review
  • NI Healthcare Review
  • Prescriber

 

Nominated Charity

  • Pharmacist Support

 

Newsletter Sign Up